Table 1 Demographics and Ephrin-B2 levels of the study groups.

From: Dysregulation of the EphrinB2−EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients

Variable

AVM

Moyamoya

Controls

P value

Gender (M/F)

15/15

2/12

10/19

0.088

Age, years

11 (8–13)

9 (3–16)

8 (4–12)

0.069

Ephrin-B2, pg/µg

35.0 (18.4–84.1)

0.0 (0.0–17.2)

11.7 (4.4–19.1)

<0.001*

  1. Comparative demographics for all study patients revealed no statistically significant differences in age or sex. The table shows summarized univariate analysis highlighting AVM-specific biomarkers compared to controls and other CNS vascular diseases. By univariate analysis, urinary EphrinB2 showed statistically significant increases in patients with AVM versus matched controls as well as versus moyamoya. *p < 0.001. Biomarker data are summarized using medians (IQRs), and a nonparametric Mann−Whitney U test was used to compare each study group to AVM.
Back to article page